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elimination of B2M and protein bound retention solutes.
Given the inferior dialytic clearance of B2M and p-cresol
by peritoneal dialysis as compared to hemodialysis,
patients on peritoneal dialysis are more dependent on
residual renal function at least as far as the removal of
these retention solutes is concerned.3 Very recently, high
serum levels of both solutes were shown to be indepen-
dently associated with increased mortality.4,5 Undoubtedly
these observations will encourage nephrologists to broad-
en their view on adequacy beyond Kt/Vurea. All together,
these data moreover provide additional support for the
integrative care concept.6
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To the Editor: Collini et al.1 report two kidney graft
recipients with post-transplant lower limbs transient joint
pain. Bone scintigraphy and magnetic resonance (MR)
imaging of the symptomatic joints showed increased tracer
uptake and bone marrow edema, respectively. As already
suggested by others, they incriminate calcineurin-inhibitors
as the cause of this syndrome.
I do not believe that this hypothesis is warranted. Indeed,
identical symptoms have been described in kidney graft
recipients before the calcineurin-inhibitors era.2 The clinical
presentation best fits with the microtraumatic hypothesis we
initially proposed.3 Indeed, in multiple reports, MR imaging
consistently showed bone marrow edema and/or hemor-
rhage. The demonstration in some patients of bands of
hyposignal within areas of bone marrow edema further
supports the notion of impaction.3 In addition, Yamamoto
et al.4 recently showed in non-transplanted patients that
similar MR imaging lesions of symptomatic areas correspond
histologically to insufficiency fracture. Bone marrow infiltra-
tion with low intensity signal on T1-weighted MR image
corresponds histologically to viable bone and marrow tissue
with associated callus, edema, and vascular granulation.4
More interestingly, the presence in some T1-weighted MR
images of a focal band beneath the articular cartilage
corresponded to a fracture line and its associated repair
tissue.4
I suggest that a microfracture is the cause of this syndrome
and that inadapted physical activity level imposed on a
fragilized post-transplant bone could favor its occurrence.
The onset of the symptoms is thus unlikely to be prevented
by a reduction of calcineurin-inhibitors dose, in contrast to
the authors’ suggestion.
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Dr Goffin makes an interesting objection to the theory of
calcineurin-inhibitor-induced pain syndrome.1 We are
familiar with his hypothesis, which we were unfortunately
unable to deal with due to limits on the length of the paper.
It is true that there is no direct demonstration of the
existence of calcineurin-inhibitor-induced pain syndrome.
The hypothesis of microtraumas occurring in bone already
weakened by steroid therapy at high doses in the
immediate post-transplant period has its validity,2,3 and
it is possible that these repeated microtraumas in such a
delicate period could cause this syndrome. Moreover, this
agrees with the descriptions made before the calcineurin-
inhibitors era,4 with the cases described under therapy
with other types of drugs5 and with the recent comments
by Yamamoto et al.6
But the hypothesis of Grotz et al.7 is equally valid: in the
transplant patients affected by this syndrome there is, in
fact, no demonstration of the ‘insufficiency fractures’
which would be at the base of the alterations which are
found with the magnetic resonance imaging. In addition,
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